Randomized, Open Label, Phase III Trial Of CP- 751,871 In Combination With Paclitaxel And Carboplatin Versus Paclitaxel And Carboplatin In Patients With Non Small Cell Lung Cancer.
Phase of Trial: Phase III
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Figitumumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms ADVIGO
- Sponsors Pfizer
- 16 Feb 2012 Planned End Date changed from 1 Feb 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 20 Oct 2011 Planned end date changed from 1 Jul 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.
- 26 Jul 2010 New source identified and integrated (M.D. Anderson Cancer Center record, 2009-0049).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History